US 12,077,563 B2
Prefusion-stabilized hMPV F proteins
Jason McLellan, Austin, TX (US); Ching-Lin Hsieh, Austin, TX (US); Scott Rush, Austin, TX (US); and Nianshuang Wang, Austin, TX (US)
Assigned to Board of Regents, The University of Texas System, Austin, TX (US)
Filed by BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, Austin, TX (US)
Filed on Jan. 12, 2024, as Appl. No. 18/411,284.
Application 18/411,284 is a continuation of application No. 18/296,771, filed on Apr. 6, 2023, granted, now 11,919,927.
Application 18/296,771 is a continuation of application No. PCT/US2021/053944, filed on Oct. 7, 2021.
Claims priority of provisional application 63/089,978, filed on Oct. 9, 2020.
Prior Publication US 2024/0140994 A1, May 2, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/08 (2006.01); C07K 14/115 (2006.01); C07K 14/135 (2006.01)
CPC C07K 14/08 (2013.01) 28 Claims
 
1. A nucleic acid molecule comprising a nucleotide sequence that encodes an amino acid sequence of an engineered protein comprising a metapneumovirus (MPV) F protein ectodomain having at least 90% identity to amino acids 19-489 of any one of SEQ ID NOs: 4-7, said engineered protein comprising an engineered disulfide bond comprising paired cysteine substitutions corresponding to T127C and N153C and/or L110C and N322C, relative to the sequence of any one of SEQ ID NOs: 4-7, wherein the nucleic acid molecule is an mRNA molecule.